International Liver Cancer Association (ILCA) white paper on hepatocellular carcinoma risk stratification and surveillance
Copyright © 2023..
Major research efforts in liver cancer have been devoted to increasing the efficacy and effectiveness of surveillance for hepatocellular carcinoma (HCC). As with other cancers, surveillance programmes aim to detect tumours at an early stage, facilitate curative-intent treatment, and reduce cancer-related mortality. HCC surveillance is supported by a large randomised-controlled trial in patients with chronic HBV infection and several cohort studies in cirrhosis; however, effectiveness in clinical practice is limited by several barriers, including inadequate risk stratification, underuse of surveillance, and suboptimal accuracy of screening tests. There are several proposed strategies to address these limitations, including risk stratification algorithms and biomarkers to better identity at-risk individuals, interventions to increase surveillance, and emerging imaging- and blood-based surveillance tests with improved sensitivity and specificity for early HCC detection. Beyond clinical validation, data are needed to establish clinical utility, i.e. increased early tumour detection and reduced HCC-related mortality. If successful, these data could facilitate a precision screening paradigm in which surveillance strategies are tailored to individual HCC risk to maximise overall surveillance value. However, practical and logistical considerations must be considered when designing and implementing these validation efforts. To address these issues, ILCA (the International Liver Cancer Association) adjourned a single topic workshop on HCC risk stratification and surveillance in June 2022. Herein, we present a white paper on these topics, including the status of the field, ongoing research efforts, and barriers to the translation of emerging strategies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:79 |
|---|---|
| Enthalten in: |
Journal of hepatology - 79(2023), 1 vom: 17. Juli, Seite 226-239 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Singal, Amit G [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clinical Conference |
|---|
| Anmerkungen: |
Date Completed 19.06.2023 Date Revised 02.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jhep.2023.02.022 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353603724 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353603724 | ||
| 003 | DE-627 | ||
| 005 | 20240108140701.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jhep.2023.02.022 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1246.xml |
| 035 | |a (DE-627)NLM353603724 | ||
| 035 | |a (NLM)36854345 | ||
| 035 | |a (PII)S0168-8278(23)00111-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Singal, Amit G |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a International Liver Cancer Association (ILCA) white paper on hepatocellular carcinoma risk stratification and surveillance |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.06.2023 | ||
| 500 | |a Date Revised 02.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023. | ||
| 520 | |a Major research efforts in liver cancer have been devoted to increasing the efficacy and effectiveness of surveillance for hepatocellular carcinoma (HCC). As with other cancers, surveillance programmes aim to detect tumours at an early stage, facilitate curative-intent treatment, and reduce cancer-related mortality. HCC surveillance is supported by a large randomised-controlled trial in patients with chronic HBV infection and several cohort studies in cirrhosis; however, effectiveness in clinical practice is limited by several barriers, including inadequate risk stratification, underuse of surveillance, and suboptimal accuracy of screening tests. There are several proposed strategies to address these limitations, including risk stratification algorithms and biomarkers to better identity at-risk individuals, interventions to increase surveillance, and emerging imaging- and blood-based surveillance tests with improved sensitivity and specificity for early HCC detection. Beyond clinical validation, data are needed to establish clinical utility, i.e. increased early tumour detection and reduced HCC-related mortality. If successful, these data could facilitate a precision screening paradigm in which surveillance strategies are tailored to individual HCC risk to maximise overall surveillance value. However, practical and logistical considerations must be considered when designing and implementing these validation efforts. To address these issues, ILCA (the International Liver Cancer Association) adjourned a single topic workshop on HCC risk stratification and surveillance in June 2022. Herein, we present a white paper on these topics, including the status of the field, ongoing research efforts, and barriers to the translation of emerging strategies | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Clinical Conference | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 700 | 1 | |a Sanduzzi-Zamparelli, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Nahon, Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Ronot, Maxime |e verfasserin |4 aut | |
| 700 | 1 | |a Hoshida, Yujin |e verfasserin |4 aut | |
| 700 | 1 | |a Rich, Nicole |e verfasserin |4 aut | |
| 700 | 1 | |a Reig, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Vilgrain, Valerie |e verfasserin |4 aut | |
| 700 | 1 | |a Marrero, Jorge |e verfasserin |4 aut | |
| 700 | 1 | |a Llovet, Josep M |e verfasserin |4 aut | |
| 700 | 1 | |a Parikh, Neehar D |e verfasserin |4 aut | |
| 700 | 1 | |a Villanueva, Augusto |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of hepatology |d 1993 |g 79(2023), 1 vom: 17. Juli, Seite 226-239 |w (DE-627)NLM012604372 |x 1600-0641 |7 nnns |
| 773 | 1 | 8 | |g volume:79 |g year:2023 |g number:1 |g day:17 |g month:07 |g pages:226-239 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jhep.2023.02.022 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 79 |j 2023 |e 1 |b 17 |c 07 |h 226-239 | ||